Company profile for Septerna

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Septerna, Inc. is a biotechnology company focused on advancing novel, oral small-molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and their small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. Septerna is building a pipeline o...
Septerna, Inc. is a biotechnology company focused on advancing novel, oral small-molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and their small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. Septerna is building a pipeline of GPCR-targeted, oral small-molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
250 East Grand Avenue, Suite 65 South San Francisco, CA 94080
Telephone
Telephone
+1 6503383533
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/25/3194257/0/en/Septerna-to-Participate-in-8th-Annual-Evercore-Healthcare-Conference.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184361/0/en/Septerna-Highlights-Company-Progress-and-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179226/0/en/Septerna-to-Participate-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/09/29/3158093/0/en/Septerna-Appoints-Veteran-Biotechnology-Leader-Keith-Gottesdiener-M-D-to-its-Board-of-Directors.html

GLOBENEWSWIRE
29 Sep 2025

https://www.globenewswire.com/news-release/2025/08/27/3139942/0/en/Septerna-to-Participate-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
27 Aug 2025

https://www.globenewswire.com/news-release/2025/08/21/3137083/0/en/Septerna-Announces-Dosing-of-the-First-Participants-in-Phase-1-Clinical-Trial-of-SEP-631-an-Oral-Small-Molecule-MRGPRX2-Negative-Allosteric-Modulator-for-the-Treatment-of-Mast-Cell.html

GLOBENEWSWIRE
21 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty